Tag Archives: Reuters

After 15 years, unheralded French biotech eyeing big payday on cancer breakthrough; “buy” signal–solid

Hidden from view just across the French border from Geneva is a little-known (at least here in the US) biotech eyeing long-awaited FDA approval for a nuclear medicine targeting the… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long

Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Humana bails Obamacare exchanges; signals beginning of the end of private insurer involvement

The News: Humana Inc. (Louisville KY) said it will leave the commercial individual insurance business effective in 2018, including coverage offered on public exchanges under the Affordable Care Act, after being unable to… Read more »

Teva’s CEO Vigodman history; sudden departure calls for fearless successor

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) suddenly found itself without a permanent CEO on Tuesday (February 7, 2017) after Erez Vigodman stepped down, leaving new management to… Read more »

Novartis repeats possible spinoff for Alcon eyecare unit; the best laid plans gone awry?

The News: Novartis AG (Basel CHE), which spent several years and more than $50 billion acquiring the Alcon eye-care company, signaled it’s ready to give up on most of the… Read more »

Valeant divests assets worth $2.1 billion to ease debt load; finally a smart move, but too little, too late?

Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »

Democrats demand probe into stock trading of Trump’s HHS nominee; GOP’s righteous indignation misplaced, puzzling

Senate Democrats on Thursday (January 5, 2016) demanded an ethics probe into Tom Price, President-elect Donald Trump’s pick for US health secretary, following a report that the fierce Obamacare critic… Read more »

20 States accuse Mylan, Teva, others of price fixing; what a banner week for the legal profession

Peggy_Marco / PixabayOne day after federal prosecutors unsealed a criminal indictment against the former CEO of Heritage Pharmaceuticals Inc. (Eatontown NJ), 20 state attorneys general filed an antitrust lawsuit against… Read more »